Gratwohl A, Hermans J
Department of Internal Medicine and Research, Kantonsspital Basel, Switzerland.
Bone Marrow Transplant. 1996 May;17 Suppl 3:S7-9.
Results of 3000 patients transplanted for chronic myeloid leukemia in Europeere used to assess outcome and main risk factors for survival (SURV), leukemia free survival (LFS), relapse incidence (RI) and transplant related mortality (TRM). More than one third (39%) of all patients are alive at + 10 years. SURV at 10 years is better for patients transplanted in first chronic phase (49%) than in accelerated phase (19%) or blast crisis (0%) due to both decreased TRM (41% versus 67% versus -) and RI (35% versus 51% versus -). For those patients transplanted in first chronic phase from an HLA-identical sibling donor with non-T-cell depleted bone marrow, modern conditioning and GVHD prevention method, median SURV has not been reached at +10 years and exceeds 55%. Other risk factors are discussed.
欧洲3000例接受慢性髓性白血病移植患者的结果被用于评估生存（SURV）、无白血病生存（LFS）、复发率（RI）和移植相关死亡率（TRM）的结局及主要危险因素。超过三分之一（39%）的患者在10年时仍存活。由于TRM降低（41%对67%对 -）和RI降低（35%对51%对 -），处于慢性期首次移植的患者10年时的SURV（49%）优于加速期（19%）或急变期（0%）移植的患者。对于那些在慢性期首次接受来自HLA相同同胞供体且未进行T细胞去除的骨髓移植、采用现代预处理和移植物抗宿主病（GVHD）预防方法的患者，10年时的中位SURV未达到且超过55%。文中还讨论了其他危险因素。
